Helmet Continuous Positive Airway Pressure Support for Severe Bronchiolitis in PICUs

June 12, 2023 updated by: Emanuele Rossetti, Bambino Gesù Hospital and Research Institute

Helmet Continous Positive Airway Pressure (CPAP) Management and Positive End Expiratory Pressure (PEEP) Level Impact on Severe Bronchiolitis Admitted in Pediatric Intensive Care Units (PICUs)

Binary randomized peep level of Helmet CPAP (1-0). The first patient enrolled will be assign to treatment 1 (10 cmH2O peep level), independently from its BSS. The following patients enrolled will be assign to treatment 0 (5 cmH2O peep level), and consecutively up to 25 patients at least.

  • 10 cmH2O peep, 50 L/min gas flow, fraction of inspired oxygen (FiO2) 0.5 on PICU admission (random 1)
  • 5 cmH2O peep, 50 L/min gas flow, FiO2 0.5 on PICU admission (random 0) If clinical and respiratory worsening, reduction of pH or partial oxygen arterial pressure (PaO2)/FiO2 occurs in the following first hour after Helmet CPAP treatment start, patients enrolled will receive endotracheal intubation, full face mask non invasive ventilation or higher peep level treatment (7.5-10 cmH2O) according to clinical evaluation, if necessary.

In investigator's experience, early worsening of severe bronchiolitis in PICU in the first hour of Helmet CPAP treatment with 10 cmH2O peep level leads to endotracheal intubation.

Study Overview

Status

Terminated

Conditions

Intervention / Treatment

Detailed Description

INTRODUCTION

Newborns and infants with severe bronchiolitis admitted in PICU (Pediatric Intensive Care Unit) are patients at high risk for invasive mechanical ventilation support. In current literature, there is lack of multicenter, prospective and randomized studies to assess and describe the impact of non invasive ventilation support among severe bronchiolitis admitted in PICU, notwithstanding the actual improvement of non invasive ventilation technique on intubation rate reduction.

Recently, we can find studies on bronchiolitis management in pediatric ward and supported with high flow nasal cannula (HFNC).

The studies on severe bronchiolitis admitted in PICU do not evaluate positive end expiratory pressure (Peep) level applied during Helmet continous positive airway pressure (CPAP) support.

According to Italian PICU Network (TIPNET) data, severe bronchiolitis admitted in PICU intubation rate is close to 10% (report 2010-2016), whatever non invasive ventilation support has been used.

Principal investigators have performed a retrospective and cohort chart review among severe bronchiolitis (82) admitted in PICU from 2011 to 2015. Early Helmet CPAP was applied to patients, but peep level has been provided according to clinician experience, because of lack of indication on this issue. Patients were admitted in PICU from Emergency department, pediatric ward and up to 72 hours of ineffective HFNC support. The investigators have studied intubation rate, length of stay, bronchiolitis severity score, virus infection, peep level and gas flow applied on Helmet CPAP.

According to preliminary results, 10 cmH2O peep level results 50 time more protective than lower (5-7.5 cmH2O) peep among flow rate of 50 L/min.

Intubation rate with peep level 10 cmH2O was 3%, while it rose over 15% among 7.5-5 cmH2O peep level. Statistically significant difference were found on length of PICU stay.

Scientific literature on Helmet CPAP noising exposure is poor. Such noising was proved to be reduced with filter application on Helmet CPAP respiratory circuit. There are not report, and we have never experienced acoustic system impairment in patients undergone Helmet CPAP.

AIMS Primary aim: to evaluate escalation therapy (higher peep, non invasive ventilation in pressure support mode, or intubation and mechanical ventilation) rate on severe bronchiolitis admitted in PICU and supported with Helmet CPAP non invasive ventilation with 10 cmH2O peep level in group 1, and 5 cmH2O peep level in group 0.

Secondary aim: to evaluate, among two study groups, length of PICU stay, pneumothorax incidence on Helmet CPAP, sedation effect during Helmet CPAP, early enteral feeding tolerance, syncytial and other respiratory virus incidence, bacterial infection and 30 days outcome.

DESIGN Prospective, randomized, cohort, controlled and multicentric study.

Population: sample size The study requires 488 patients, enrolled among 20 national and international PICU. Sample size have been calculated on preliminary results of our retrospective chart review; we hypothesize that intubation rate with 5 cmH2O peep level is 15% and application of 10 cmH2O peep level may reduce it to 50%. According to these hypothesis, we need 244 patients for each group to have 5% of significativity level and 80% of study power.

Length of study 24 months

Procedure and methods

Selection and patient enrollment Severe bronchiolitis admitted in PICU and requiring respiratory support.

Intervention

Binary randomized peep level of Helmet CPAP (1-0). The first patient enrolled will be assign to treatment 1 (10 cmH2O peep level), independently from its BSS. The following patients enrolled will be assign to treatment 0 (5 cmH2O peep level), and consecutively up to 25 patients at least.

  • 10 cmH2O peep, 50 L/min gas flow, FiO2 0.5 on PICU admission (random 1)
  • 5 cmH2O peep, 50 L/min gas flow, FiO2 0.5 on PICU admission (random 0) If clinical and respiratory worsening, reduction of pH or PaO2/FiO2 occurs in the following first hour after Helmet CPAP treatment start, patients enrolled will receive endotracheal intubation, full face mask non invasive ventilation or higher peep level treatment (7.5-10 cmH2O) according to clinical evaluation, if necessary.

In investigators' experience, early worsening of severe bronchiolitis in PICU in the first hour of Helmet CPAP treatment with 10 cmH2O peep level leads to endotracheal intubation.

STUDY PLAN Application of a standard treatment protocol for all patients enrolled. It is the same standard of care applied to treat these patients in our PICU in the last 2 years. Of course, patients who will not be enrolled in the study will be supported and treated with the best feasible care.

  • Registration of the modified Wood's Clinical Asthma score (mWCAS) for severe bronchiolitis admitted in PICU (Bronchiolitis Severity Score-BSS)
  • clarithromycin prophylaxis for newborns (up to 30 days old), or I generation cephalosporine for older infants, if high fever, lung opacities or high inflammation markers occurs (PCR, procalcitonin, White body cells)
  • volume replacement (20 ml/kg of sodium chloride solution or albumine 5%) in 60 min
  • morphine ev bolus: 20 mcg/kg in 2 min and following 5 mcg/kg/h infusion (or other sedatives according to local PICU investigator)
  • nasogastric tube placement and early enteral feeding 4-6 hours after admission (5-10 ml/h)
  • desamethasone 0.2 mg/kg x3/die ev (according to local PICU investigator ).
  • proton pump inhibitors or H2 receptor antagonist (according to local PICU investigator).
  • aerosol therapy 4 time/die: sodium chloride hypertonic solution 3% (or sodium chloride 0.9%) 2 ml with ipratropium bromide .
  • Arterial blood gas exam (ABE) before Helmet CPAP application and in the following 1,12 24, and 48 hours; arterial catheter positioning is preferred (or arterial blood sampling by direct arterial puncture according to local PICU practice).
  • Pharyngeal swab for molecular analysis to detect viral DNA will be performed on PICU admission, if not yet performed.
  • occipital and neck skin protection will be used to avoid Helmet CPAP pressure sores.
  • each Helmet will be provided of a filter to reduce noise inside it.
  • Helmet gas will flow through heat-moisture device switched on 5 min/hour

Only patients whose parents have signed written informed consent will be enrolled in this study. Any direct follow up is supposed after PICU discharge. Monitoring of hospital discharge will be followed by intranet database of the participant hospital.

Study Type

Interventional

Enrollment (Actual)

126

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • Italy
    • Lazio
      • Rome, Lazio, Italy, 00100
        • Bambino Gesù Children's Hospital

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

8 months to 1 year (Child)

Accepts Healthy Volunteers

No

Description

Inclusion Criteria:

  • Patients of 38 weeks of gestational age up to 18 months old, admitted in PICU for severe bronchiolitis, whose parents have signed written informed consent to enroll the child in the study.
  • Patients with severe bronchiolitis moved from emergency department, pediatric ward, and supported up to 72 hours with HFNC or O2 therapy.

Exclusion Criteria:

  • Severe congenital malformation Inborn congenital error Neonatal or postnatal neurologic disorder Parents refusal to study participation Presence or supposed pneumothorax on chest X-ray or lung ultrasound

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Supportive Care
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Double

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Active Comparator: group 1
high level support
Device: 10 cmH2O peep
positive end expiratory pressure
No Intervention: group 0
low level support

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
incidence of intubation following Helmet CPAP treatment
Time Frame: 7 days
to evaluate intubation rate on severe bronchiolitis admitted in PICU and supported with Helmet CPAP non invasive ventilation with 10 peep level in group 1, and 5 peep level in group 0.
7 days
incidence of pneumothorax following Helmet CPAP treatment
Time Frame: 72 hours
pneumothorax occurrence
72 hours

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
length of stay
Time Frame: days 30
length of PICU stay
days 30

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Bambino Gesù Hospital and Research Institute

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

November 2, 2016

Primary Completion (Actual)

May 1, 2020

Study Completion (Actual)

May 1, 2020

Study Registration Dates

First Submitted

November 17, 2016

First Submitted That Met QC Criteria

November 29, 2016

First Posted (Estimated)

November 30, 2016

Study Record Updates

Last Update Posted (Actual)

June 15, 2023

Last Update Submitted That Met QC Criteria

June 12, 2023

Last Verified

June 1, 2023

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • 1239_OPBG_2016

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

UNDECIDED

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Critically Ill Severe Bronchiolitis

Clinical Trials on 10 cmH2O peep

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Kenya

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

3
Subscribe